Allergan Presents Data at the 2016 American Academy of Dermatology (AAD) Annual Meeting in Washington D.C.

DUBLIN, March 4, 2016 /PRNewswire/ -- Allergan plc (NYSE: AGN), today announced that its data will be featured during the 2016 American Academy of Dermatology (AAD) Annual Meeting in Washington D.C., March 4 – 8, 2016.

Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO  

The scheduled times (noted in local Eastern Time) of the 14 Allergan presentations, presentation titles, locations and lead presenter(s) are as follows: 

• Age and Gender as Predictors of Treatment Outcomes with Once-Daily Dapsone 7.5% Topical Gel for Acne Vulgaris
  • Date and Time: Friday, March 4, 8:25 – 8:30 AM
  • Room: Hall D, E-Poster Presentation Center 1
  • Categories: Aesthetic Dermatology, Acne

• Once-Daily Topical Dapsone Gel 7.5% for Acne Vulgaris: Pooled Efficacy and Safety Data from Two Pivotal Studies
  • Date and Time: Friday, March 4, 10:00 – 10:10 AM
  • Room: Hall D, E-Poster Presentation Center 1
  • Categories: Aesthetic Dermatology, Acne
     
• Self-Reported Characteristics Associated with the Signs of Facial Aging by Race/Ethnic Group and Fitzpatrick Skin Type among a Diverse, Multinational Sample
  • Date and Time: Saturday, March 5, 2016 2:12 PM
  • Room: Late-breaking Research Forum-Procedural Dermatology, Room 146C
  • Categories: Aesthetic Dermatology

• Improvement in Aging Appearance, Social Confidence, and Psychological Well-Being With Combined Facial Aesthetic Treatment Comprising OnabotulinumtoxinA, Dermal Fillers, and Bimatoprost: HARMONY Study Outcomes
  • Date and Time: Friday, March 4, 2016 1:40 – 1:45 PM
  • Room: Hall D, E-Poster Presentation Center 1
  • Categories: Aesthetic Dermatology

• Substantial Improvements in Subject-Assessed Satisfaction With Appearance From Combined Facial Aesthetic Treatment With OnabotulinumtoxinA, Dermal Fillers, and Bimatoprost: Primary Results From the HARMONY Study
  • Date and Time: Friday, March 4, 2016 3:15 – 3:20 PM
  • Room: Hall D, E-Poster Presentation Center 1
  • Categories: Aesthetic Dermatology

• Deoxycholic Acid Injection (ATX-101) Treatment Markedly Reduces Preplatysmal Fat
  • Date and Time: Friday, March 4, 2016 12:45 – 12:50 PM
  • Room: Hall D, E-Poster Presentation Center 1
  • Categories: Aesthetic Dermatology

• Safety and Effectiveness of the Hyaluronic Acid Injectable Gel, VYC-15L, for Lip and Perioral Enhancement: Multicenter, Randomized, Controlled Trial
  • Date and Time: Friday, March 4, 2016 3:05 – 3:10 PM
  • Room: Hall D, E-Poster Presentation Center 1
  • Categories: Aesthetic Dermatology

• Facial Treatment Preferences in Aesthetically-Oriented Men
  • Date and Time: Friday, March 4, 2016 1:20 – 1:25 PM
  • Room: Hall D, E-Poster Presentation Center 1
  • Categories: Aesthetic Dermatology

• Understanding the Male Perspective on Office-Based Aesthetic Procedures: Awareness, Motivating Factors, and Barriers
  • Date and Time: Friday, March 4, 2016 3:30 – 3:35 PM
  • Room: Hall D, E-Poster Presentation Center 1
  • Categories: Aesthetic Dermatology

• Immediate and Long-Term Effects of a Topical Serum with Five Forms of Hyaluronic Acid on Facial Wrinkles and Intrinsic Skin Moisture Content"
  • Date and Time: Friday, March 4, 2016 1:30 – 1:35 PM
  • Room: Hall D, E-Poster Presentation Center 1
  • Categories: Aesthetic Dermatology

• A Novel Blend of Antioxidants Minimizes UV-Induced DNA Damage Markers in Human Skin
  • Date and Time: Friday, March 4, 2016 11:30 – 11:35 AM
  • Room: Hall D, E-Poster Presentation Center 1
  • Categories: Aesthetic Dermatology

• Clinical Effects of a Novel Blend of Antioxidants on Subjects with Moderate to Severe Facial Photodamage
  • Date and Time: Friday, March 4, 2016 12:25 – 12:30 PM
  • Room: Hall D, E-Poster Presentation Center 1
  • Categories: Aesthetic Dermatology

• Pilot Study: Protective Effects Against Infrared Radiation-Induced Heat from a Proprietary Blend of Antioxidants with Sunscreen
  • Date and Time: Friday, March 4, 2016 2:30 – 2:35 PM
  • Room: Hall D, E-Poster Presentation Center 1
  • Categories: Aesthetic Dermatology

• Safety and Effectiveness of the Hyaluronic Acid Injectable Gel, VYC-17.5L, for Correction of Nasolabial Folds: Multicenter, Randomized, Within-Subject Controlled Trial
  • Date and Time: Friday, March 4, 2016 3:10 – 3:15 PM
  • Room: Hall D, E-Poster Presentation Center 1
  • Categories: Aesthetic Dermatology

About Allergan 
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model – Growth Pharma.  Allergan is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world.

Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry and a leading position in the submission of generic product applications globally.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives.
For more information, visit Allergan's website at www.Allergan.com.

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Quarterly Report on Form 10-Q for the quarter ended September 30, 2015 (such periodic public filings having been filed under the "Actavis plc" name). Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

CONTACTS:  

Investors:   
Lisa DeFrancesco  
(862) 261-7152

Media:
Mark Marmur
(862) 261-7558

SOURCE Allergan plc

Related Links

http://www.allergan.com